Compare · ADXS vs TRIL
ADXS vs TRIL
Side-by-side comparison of Advaxis, Inc. (ADXS) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXS and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL is the larger of the two at $1.94B, about 34.6x ADXS ($56.0M).
- TRIL has more recent analyst coverage (5 ratings vs 0 for ADXS).
- Company
- Advaxis, Inc.
- Trillium Therapeutics Inc.
- Price
- $0.25-15.74%
- $19.30-3.45%
- Market cap
- $56.0M
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 5
Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest ADXS
- OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
- SEC Form 15-12G filed by Advaxis, Inc.
- SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)
- Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 10-K filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo